E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
SEASONAL ALLERGIC RHINITIS |
|
E.1.1.1 | Medical condition in easily understood language |
SEASONAL ALLERGIC RHINITIS |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10039776 |
E.1.2 | Term | Seasonal allergic rhinitis |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this multicenter, randomized, double blind, controlled, clinical study is to demonstrate the therapeutic clinical equivalence of two mometasone nasal sprays in the relief of the signs and symptoms of seasonal allergic rhinitis, in term of change from baseline in average instantaneous PM Total Nasal Symptom Scores (TNSS the sum of individual symptom scores) recorded in subject’s diary. |
|
E.2.2 | Secondary objectives of the trial |
Efficacy monitoring in term of assessment of evolution during the study treatments of AM total nasal symptoms score , AM total non nasal symptoms score and PM total non nasal symptoms score recorded in subject’s diary .
Overall Subject’s and Physician’s global assessment.
Clinical Global Improvement (CGI) evaluation
Quality of life evaluation (RQLQ)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male and female, 12 years until 65 years old.
• Subjects with a minimum of 2 years history of seasonal allergic rhinitis
• Documented positive allergy skin test, either intradermal or epicutaneous, and or validated IgE (RAST, Western Blot, ELISA)*
• Seasonal allergic rhinitis symptoms present at the time of the study randomization: a TNSS score of at least 6 up to a maximum score of 12 at the day of randomization visit.
• Subjects capable of recording seasonal nasal allergy symptoms throughout a diary to be filled-in every day for all study duration.
• Subjects able to provide written inform consent. For Subjects under the age of majority the parent or legal guardian should sign the consent form and the child will be required to sign a Subject "assent" form.
|
|
E.4 | Principal exclusion criteria |
• Females pregnant, lactating or planning to get pregnant during the study.
• Non seasonal allergic rhinitis
• Clinically significant nasal disease (other than SAR) or nasal surgery or significant nasal structural abnormalities
• Bacterial or viral infection of the upper or lower respiratory tract ,nasal sinus or middle ear within the previous 30 days.
• Presence of a significant pulmonary disease including asthma requiring use of controller medication
• Subject previously treated with mometasone within the previous 30 days
• Subject who have received anti-allergy immunotherapy (desensitising subjects with increase of allergen challenges) in the previous 2 years or are still receiving this kind of therapy.
• Subject with a history of tuberculosis.
• Subject with glaucoma, cataracts, ocular herpes simplex, conjunctivitis or other eye infection.
• Subject with a recent exposure (30 days) or at risk of being exposed to chicken pox or measles.
• Use of concomitant medication(s) that could affect the assessment of efficacy and safety of study treatment
• Any known hypersensitivity to mometasone, other steroids or any of the components of the study nasal spray.
• Subjects with a history of alcohol or drug abuse.
• Congenital or acquired severe immunodeficiency or know immunodeficiency virus (HIV) infection
• Significant psychiatric disease that in the Investigator would affect subject safety or influence study outcome
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy evaluation is to demonstrate the therapeutic clinical equivalence among a generic mometasone product and the Nasonex Nasal Spray through evaluation of TNSS PM . |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 2 weeks of treatment |
|
E.5.2 | Secondary end point(s) |
Efficacy:
Evaluation of TNSS AM and TNNSS AM and PM;
The patient’s Global Assessment for Efficacy and Safety and the investigator’s Global Assessment for Efficacy and Safety
Clinical Global Improvement (CGI) evaluation.
Quality of life (QoL) evaluation (only for adult subjects)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After 2 weeks of treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
DEMONSTRATE THE THERAPEUTIC CLINICAL EQUIVALENCE OF TWO MOMETASONE NASAL SPRAYS |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 14 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |